Steris PLC 8-K filings

STERIS plc's 2026 Annual General Meeting saw overwhelming shareholder approval for director elections, auditor ratification, executive compensation, and share issuance authorities.

STERIS plc announced its fiscal 2027 first quarter financial results, reporting a 7% increase in total revenue to $1.5 billion and a strategic restructuring plan for its formulated chemistries business.

STERIS plc announced robust financial results for fiscal year 2026, with revenue up 9% and adjusted EPS increasing to $10.17, alongside a new $1 billion share repurchase program.

STERIS plc announced the appointment of Pierre Boulud to its Board of Directors, effective May 5, 2026, bringing extensive global leadership and strategic expertise.

STERIS plc announced an amendment to its transition agreement with former CFO Michael J. Tokich, extending his part-time senior financial advisor role through March 31, 2027, with adjusted compensation and benefits.

STERIS plc announced robust financial results for its fiscal 2026 third quarter, with total revenue up 9% and adjusted EPS increasing to $2.53, while reaffirming its full-year outlook.

STERIS plc reported strong fiscal 2026 second-quarter results, with total revenue up 10% and adjusted EPS increasing to $2.47, leading to an upward revision of its full-year financial guidance.

STERIS plc reported strong fiscal Q1 2026 results with revenue and EPS exceeding expectations, alongside a planned CFO transition and board updates.

STERIS plc announced that Dr. Richard Steeves will retire from its Board of Directors effective July 31, 2025, after 10 years of service.

STERIS plc reports a 6% increase in fiscal 2025 revenue and provides a positive outlook for fiscal 2026, anticipating further growth.

STERIS plc subsidiary, Isomedix, has reached agreements to settle ethylene oxide-related personal injury claims in Illinois for up to $48.15 million.

STERIS plc reports a 6% increase in total revenue and constant currency organic revenue for Q3 2025, with adjusted EPS rising to $2.32, and updates its fiscal year outlook.

STERIS plc announced a 7% increase in total revenue and a rise in adjusted EPS to $2.14 for the second quarter of fiscal year 2025, while reiterating its full-year outlook.

STERIS plc has entered into a new $1.1 billion revolving credit agreement, replacing its previous facility and providing funds for general corporate purposes and working capital.

STERIS plc announced an 8% increase in total revenue and a 6% growth in constant currency organic revenue for the first quarter of fiscal year 2025, with adjusted EPS rising to $2.03.

STERIS plc successfully held its 2024 Annual General Meeting, electing directors and approving proposals including the ratification of auditors and executive compensation.

STERIS plc finalized the sale of its Dental business segment to HuFriedy Group for $787.5 million, with potential for an additional $12.5 million based on future revenue targets.

STERIS plc reported a 12% increase in fiscal 2024 revenue to $5.5 billion and announced a targeted restructuring plan expected to yield $25 million in annual EBIT improvement.

STERIS has agreed to sell its Dental business segment to Peak Rock Capital for $787.5 million in cash, plus a potential $12.5 million earnout.

STERIS plc announced a 15% increase in third-quarter revenue and updated its fiscal 2024 outlook, driven by strong performance in its Healthcare segment.